Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults

McIntosh H
Record ID 32013000415
Authors' recomendations: In the only randomised controlled trial (RCT), TAVI significantly reduced the risk of death from any cause after one year compared with conservative management in patients who were not suitable candidates for surgery. In the RCT, TAVI was associated with a significantly higher incidence of major vascular complications and a higher incidence of major strokes. There are currently no published randomised trials comparing TAVI with surgical aortic valve replacement. There are few data on long-term outcomes following TAVI. There is limited information on the impact of TAVI on quality of life compared with alternative interventions. There is insufficient information to reliably estimate the cost effectiveness of TAVI. Patient selection for TAVI should be undertaken by a multidisciplinary team.
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United Kingdom (Scotland)
MeSH Terms
  • Heart Valve Prosthesis Implantation
  • Cardiac Catheterization
Organisation Name: Scottish Health Technologies Group
Contact Address: Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name:
Contact Email:
Copyright: Healthcare Improvement Scotland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.